Bioventus Inc. (BVS)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Bioventus Inc. reported revenue of $568.09M, down 0.9% from the prior year. The company was profitable, with a net margin of 4.0% and a gross margin of 68.3%. It held $683.56M in total assets against $455.11M in total liabilities.
Key ratios (FY2025)
68.3%
Gross margin
9.5%
Operating margin
4.0%
Net margin
12.3%
Return on equity
-0.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $568.09M | $573.28M | $512.35M | $512.12M | $430.90M | $321.16M | $340.14M |
| Cost of Revenue | $179.93M | $185.05M | $184.15M | $181.04M | $128.19M | $87.64M | $90.94M |
| Gross Profit | $388.16M | $388.23M | $328.19M | $331.08M | $302.71M | $233.52M | $249.21M |
| Operating Income | $53.98M | -$15.20M | -$81.72M | -$167.23M | $12.06M | $21.24M | $31.19M |
| Net Income | $22.73M | -$36.12M | -$156.23M | -$158.70M | $19.38M | $16.41M | $6.85M |
| EPS (Diluted) | $0.33 | $-0.56 | $-2.49 | $-2.59 | $-0.15 | — | — |
| Total Assets | $683.56M | $727.96M | $810.91M | $1.37B | $1.23B | $494.47M | — |
| Total Liabilities | $455.11M | $542.35M | $589.79M | $960.43M | $618.21M | $350.31M | — |
| Shareholders' Equity | $184.10M | $147.94M | $173.59M | $325.24M | $458.92M | — | — |
| Cash & Equivalents | $51.24M | $41.58M | $36.96M | $30.19M | $43.93M | $86.84M | — |
| Operating Cash Flow | $74.67M | $38.80M | $15.34M | -$13.54M | $22.99M | $71.80M | $40.71M |
| Capital Expenditures | $2.56M | $1.01M | $7.36M | $1.48M | $13.52M | $16.58M | $2.34M |
| Shares Outstanding | 68.91M | 64.55M | 62.65M | 61.39M | 45.47M | — | — |